-
Feb 10, 2020, 11:22 am140 ptsScienceDaily
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a new study.
Trending Today on EcoTopical
Welcome to EcoTopical Your daily eco-friendly green news aggregator.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.